Product Name :USP27X polyclonal antibody
Application_all :WB (1/500 - 1/1000)
Background :Ubiquitin carboxyl-terminal hydrolase 27: Deubiquitinase involved in innate antiviral immunity by mediating deubiquitination of CGAS and RIGI . Negatively regulates RIGI by mediating 'Lys-63'-linked deubiquitination of RIGI, inhibiting type I interferon signaling . Also regulates 'Lys-63'-linked ubiquitination level of MDA5/IFIH1 . Acts as a positive regulator of the cGAS-STING pathway by catalyzing 'Lys-48'-linked deubiquitination of CGAS, thereby promoting its stabilization . Can reduce the levels of BCL2L11/BIM ubiquitination and stabilize BCL2L11 in response to the RAF-MAPK-degradation signal (By similarity). By acting on BCL2L11 levels, may counteract the anti-apoptotic effects of MAPK activity (By similarity)
Product :1mg/ml in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Purification&Purity :The antibody was purified by immunogen affinity chromatography.
Storage&Stability :Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :Recognizes endogenous levels of USP27X protein.
Note :For research use only, not for use in diagnostic procedure.
Alternative Name :USP22L; USP27; Ubiquitin carboxyl-terminal hydrolase 27; Deubiquitinating enzyme 27; Ubiquitin carboxyl-terminal hydrolase 22-like; Ubiquitin thioesterase 27; Ubiquitin-specific-processing protease 27; X-linked ubiquitin carboxyl-terminal hydrolase 27
Immunogen :A synthetic peptide encompassing a sequence within the N-terminal region of human USP27X.
Modification :Unmodification
